BioSpace

FDA peptide policy risks undermining drug development and patient safety

By allowing compounding pharmacies to produce certain unapproved peptides, the Department of Health and Human Services could, in the short term, put patients in harm’s way. Longer term, the policy shift threatens the industry that brings new medicines to market.

By BioSpace

1 min read
FDA peptide policy risks undermining drug development and patient safety
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights